Beijing SL Pharmaceutical Co Ltd (002038) — Cash Flow Reinvestment Rate
Beijing SL Pharmaceutical Co Ltd (002038) has a Cash Flow Reinvestment Rate of 0.17x as of September 2025, reinvesting CN¥11.35 Million (capex CN¥11.35 Million ) from operating cash flow of CN¥66.55 Million. Explore 002038 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Beijing SL Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2003–2025)
Historical reinvestment intensity for Beijing SL Pharmaceutical Co Ltd across 23 annual periods. Also explore Beijing SL Pharmaceutical Co Ltd total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Beijing SL Pharmaceutical Co Ltd (2003–2025)
Year-by-year capital reinvestment analysis for Beijing SL Pharmaceutical Co Ltd. For live market cap and broader valuation context, see Beijing SL Pharmaceutical Co Ltd (002038) market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.03x | CN¥265.61 Million | CN¥257.66 Million | CN¥192.97 Million | ▼ -33.1% |
| 2024 | 1.54x | CN¥347.57 Million | CN¥225.49 Million | CN¥347.38 Million | ▲ +160.9% |
| 2023 | 0.59x | CN¥271.93 Million | CN¥460.20 Million | CN¥218.36 Million | ▼ -67.3% |
| 2022 | 1.81x | CN¥703.89 Million | CN¥389.82 Million | CN¥163.49 Million | ▲ +252.7% |
| 2021 | 0.51x | CN¥237.87 Million | CN¥464.63 Million | CN¥236.91 Million | ▼ -73.9% |
| 2020 | 1.96x | CN¥816.62 Million | CN¥415.84 Million | CN¥255.95 Million | ▲ +238.9% |
| 2019 | 0.58x | CN¥385.77 Million | CN¥665.83 Million | CN¥272.78 Million | ▼ -37.8% |
| 2018 | 0.93x | CN¥451.84 Million | CN¥485.17 Million | CN¥227.37 Million | ▼ -23.1% |
| 2017 | 1.21x | CN¥460.83 Million | CN¥380.72 Million | CN¥229.65 Million | ▼ -34.6% |
| 2016 | 1.85x | CN¥734.87 Million | CN¥396.86 Million | CN¥164.21 Million | ▲ +109.2% |
| 2015 | 0.89x | CN¥446.93 Million | CN¥504.87 Million | CN¥129.68 Million | ▲ +172.6% |
| 2014 | 0.32x | CN¥151.01 Million | CN¥465.00 Million | CN¥151.01 Million | ▲ +3.1% |
| 2013 | 0.32x | CN¥109.48 Million | CN¥347.41 Million | CN¥109.48 Million | ▼ -49.3% |
| 2012 | 0.62x | CN¥247.89 Million | CN¥398.60 Million | CN¥247.89 Million | ▲ +94.6% |
| 2011 | 0.32x | CN¥73.05 Million | CN¥228.59 Million | CN¥73.05 Million | ▲ +76.8% |
| 2010 | 0.18x | CN¥43.04 Million | CN¥238.13 Million | CN¥43.04 Million | ▲ +3.5% |
| 2009 | 0.17x | CN¥30.46 Million | CN¥174.41 Million | CN¥30.46 Million | ▲ +43.7% |
| 2008 | 0.12x | CN¥23.61 Million | CN¥194.32 Million | CN¥23.61 Million | ▼ -59.7% |
| 2007 | 0.30x | CN¥26.61 Million | CN¥88.36 Million | CN¥26.61 Million | ▼ -73.3% |
| 2006 | 1.13x | CN¥64.95 Million | CN¥57.55 Million | CN¥64.95 Million | ▼ -34.0% |
| 2005 | 1.71x | CN¥81.24 Million | CN¥47.48 Million | CN¥81.24 Million | ▲ +201.6% |
| 2004 | 0.57x | CN¥17.73 Million | CN¥31.26 Million | CN¥17.73 Million | ▲ +5.5% |
| 2003 | 0.54x | CN¥16.43 Million | CN¥30.55 Million | CN¥16.43 Million | — |